Executive Search Success Story: Building Commercial & Medical Leadership for a Rare Disease Pharmaceutical Company

How JRG Partners built the commercial, medical, and patient-advocacy leadership team behind a rare disease pharmaceutical company’s orphan-drug launches — recruiting across eight leadership mandates through a confidential search.

The Challenge

A rapidly growing rare disease pharmaceutical company was preparing for multiple product launches while advancing a robust pipeline of orphan drug therapies targeting underserved patient populations. As clinical programs progressed and commercialization activities accelerated, executive leadership recognized the need to strengthen its leadership team with highly specialized pharmaceutical executives. Leadership identified several pressures:

• Limited availability of executives with rare disease expertise
• Growing competition for specialized biotech and orphan drug talent
• Complex regulatory and market access requirements
• Need for leaders experienced in small patient population commercialization
• Succession concerns within key executive functions
• Demand for executives capable of scaling operations while maintaining patient-centric strategies

The Board and executive leadership team determined that multiple strategic hires would be necessary to support the company’s next phase of growth. The confidential mandate covered a Chief Commercial Officer, Chief Medical Officer, VP Market Access, VP Regulatory Affairs, VP Clinical Development, Head of Patient Advocacy, Medical Affairs Executives, and Rare Disease Commercial Leaders. The organization required a search partner with deep expertise in rare disease pharmaceuticals, biotechnology, regulatory affairs, and commercial leadership.

Why They Chose JRG Partners

After evaluating several executive search firms, the client selected JRG Partners for four reasons:

Specialized Rare Disease & Biopharma Recruiting Expertise

JRG Partners maintains dedicated executive search practices focused on biotechnology, rare disease therapeutics, pharmaceuticals, life sciences, and executive leadership recruitment.

Access to Elite Rare Disease Talent

Many of the industry’s most successful rare disease executives are not actively pursuing new opportunities. Through extensive industry relationships and targeted market intelligence, JRG Partners identified exceptional passive candidates unavailable through traditional recruiting channels.

Deep Understanding of Orphan Drug Markets

Successful rare disease leaders must navigate regulatory complexity, patient advocacy partnerships, market-access challenges, clinical development, and commercialization strategies. Our recruiters understand these highly specialized requirements.

Global Talent Reach

The search required executive talent across major life sciences hubs including Boston, San Francisco, San Diego, Philadelphia, New York, Basel, London, and Cambridge.

Our Executive Search Strategy

Phase 1 — Leadership Assessment

Our consultants partnered with executive leadership, board members, and investors to identify growth objectives, commercialization priorities, clinical-development goals, leadership-capability gaps, succession-planning risks, and future organizational requirements. Rather than recruiting solely for immediate openings, we developed executive profiles aligned with the company’s long-term strategic vision.

Phase 2 — Talent Mapping

JRG Partners conducted a comprehensive market-mapping initiative covering rare disease pharmaceutical companies, biotechnology organizations, orphan drug developers, gene therapy companies, specialty pharmaceutical firms, global life sciences organizations, and venture-backed biotech businesses. More than 500 executive and senior leadership profiles were evaluated across global markets.

Phase 3 — Executive Engagement

Using a research-driven approach, our consultants discreetly engaged leaders with demonstrated success in rare disease commercialization, regulatory strategy, clinical-development leadership, market-access initiatives, patient-advocacy partnerships, medical affairs management, product-launch execution, and global market expansion. Only candidates with measurable achievements and strong cultural alignment advanced.

Phase 4 — Assessment & Selection

Each finalist underwent extensive evaluation focused on rare disease expertise, strategic leadership capabilities, regulatory knowledge, commercial-execution experience, team-building effectiveness, stakeholder-management skills, cultural fit, and long-term retention potential.